ATE420115T1 - Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs - Google Patents

Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs

Info

Publication number
ATE420115T1
ATE420115T1 AT03760023T AT03760023T ATE420115T1 AT E420115 T1 ATE420115 T1 AT E420115T1 AT 03760023 T AT03760023 T AT 03760023T AT 03760023 T AT03760023 T AT 03760023T AT E420115 T1 ATE420115 T1 AT E420115T1
Authority
AT
Austria
Prior art keywords
mab
monoclonal antibody
aurora
optionally
diagnosing
Prior art date
Application number
AT03760023T
Other languages
English (en)
Inventor
Claude Prigent
Anne Martin
Original Assignee
Centre Nat Rech Scient
Sang Bretagne Ets Franc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Sang Bretagne Ets Franc filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE420115T1 publication Critical patent/ATE420115T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03760023T 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs ATE420115T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0207212A FR2840905B1 (fr) 2002-06-12 2002-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers

Publications (1)

Publication Number Publication Date
ATE420115T1 true ATE420115T1 (de) 2009-01-15

Family

ID=29595167

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03760023T ATE420115T1 (de) 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs

Country Status (9)

Country Link
US (1) US7514231B2 (de)
EP (1) EP1511771B1 (de)
JP (1) JP4555681B2 (de)
AT (1) ATE420115T1 (de)
AU (1) AU2003255671A1 (de)
CA (1) CA2489214C (de)
DE (1) DE60325725D1 (de)
FR (1) FR2840905B1 (de)
WO (1) WO2003106500A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255715T3 (es) * 1995-12-18 2006-07-01 Sugen, Inc. Diagnostico y tratamiento de transtornos relacionados con la aur-1 y/o la aur-2.

Also Published As

Publication number Publication date
CA2489214A1 (fr) 2003-12-24
AU2003255671A1 (en) 2003-12-31
EP1511771A1 (de) 2005-03-09
WO2003106500A1 (fr) 2003-12-24
AU2003255671A8 (en) 2003-12-31
JP4555681B2 (ja) 2010-10-06
FR2840905B1 (fr) 2006-07-07
FR2840905A1 (fr) 2003-12-19
DE60325725D1 (de) 2009-02-26
JP2006513135A (ja) 2006-04-20
EP1511771B1 (de) 2009-01-07
CA2489214C (fr) 2013-08-06
US7514231B2 (en) 2009-04-07
US20070117163A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
Knittel et al. Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-) fibroblast subpopulations in hepatic tissue repair
DE69929185T2 (de) Tumormarker
AU2014280846B2 (en) Methods for detecting prostate cancer
RU2007139912A (ru) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
ATE538809T1 (de) Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
BRPI0311233B8 (pt) métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
ES2569663T3 (es) Procedimiento de diagnóstico
DE60025526D1 (de) Elisa für vegf
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
DE602005017519D1 (de) Automatische glykofingerabdruck-strategie
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
Ratkaj et al. Microarray analysis of Dupuytren’s disease cells: the profibrogenic role of the TGF-β inducible p38 MAPK pathway
Hagedorn et al. Integration of zebrafish fin regeneration genes with expression data of human tumors in silico uncovers potential novel melanoma markers
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE331958T1 (de) Verfahren zum nachweis und zur quantifizierung von -aus soliden tumoren abstammenden- zirkulierenden tumorzellen
ATE419533T1 (de) Verfahren/präparat zur erkennung von pankreaskrebs
ATE420115T1 (de) Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
ATE500275T1 (de) Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties